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Abstract: The risk for venous thromboembolism (VTE) in medical patients is high, but risk 
assessment is rarely performed because there is not yet a good method to identify candidates 
for prophylaxis. 
Purpose: To perform a systematic review about VTE risk factors (RFs) in hospitalized medi-
cal patients and generate recommendations (RECs) for prophylaxis that can be implemented 
into practice. 
Data sources: A multidisciplinary group of experts from 12 Brazilian Medical Societies 
searched MEDLINE, Cochrane, and LILACS. 
Study selection: Two experts independently classiﬁ  ed the evidence for each RF by its scien-
tiﬁ  c quality in a standardized manner. A risk-assessment algorithm was created based on the 
results of the review. 
Data synthesis: Several VTE RFs have enough evidence to support RECs for prophylaxis in 
hospitalized medical patients (eg, increasing age, heart failure, and stroke). Other factors are 
considered adjuncts of risk (eg, varices, obesity, and infections). According to the algorithm, 
hospitalized medical patients 40 years-old with decreased mobility, and 1 RFs should receive 
chemoprophylaxis with heparin, provided they don’t have contraindications. High prophylactic 
doses of unfractionated heparin or low-molecular-weight-heparin must be administered and 
maintained for 6–14 days. 
Conclusions: A multidisciplinary group generated evidence-based RECs and an easy-to-use 
algorithm to facilitate VTE prophylaxis in medical patients.
Keywords: embolism and thrombosis, risk factors, prevention and control, heparin, risk-
assessment, guideline
Introduction
Venous thromboembolism (VTE) represents a spectrum of diseases that include deep 
vein thrombosis, central venous catheters associated thrombosis (CVC-thrombosis), 
and pulmonary embolism (PE). Both clinically symptomatic and asymptomatic 
episodes of VTE are common in hospitalized patients (Goldhaber and Tapson 2004), 
and are associated with high mortality (Maffei et al 1980; Anderson et al 1991; Lind-
blad et al 1991; Golin et al 2002). Autopsy studies have shown that approximately 
10% of all inpatients deaths are due to PE, but only a small proportion of PE are 
suspected before death (Pineda et al 2001; Yoo and Mendes 2004). Until the mid 90s, 
most studies focused on surgical patients, given their high incidence of VTE. As a 
consequence, the notion about the need for VTE prophylaxis in surgical populations 
gained acceptance. More recently, randomized controlled trials have highlighted the 
fact that the risk of VTE in patients with medical conditions is similar to that of some 
surgical patients (Bergmann and Neuhart 1996; Harenberg et al 1996; Lechler et al 
1996; Samama et al 1999; Kleber et al 2003; Leizorovicz et al 2004). Additionally, Vascular Health and Risk Management 2007:3(4) 534
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some epidemiological studies have demonstrated that more 
than half of patients who develop symptomatic VTE have 
medical, not surgical conditions (Goldhaber et al 2000). In 
the registry RIETE (Monreal et al 2004), only 28% of acutely 
ill medical patients with decreased mobility had received 
prophylaxis, while 67% of surgical patients did. During the 
follow-up of these patients, both PE and fatal bleedings were 
more common in medical patients, underlying the need for 
adequate prophylactic regimens in this particular subset of 
patients. Therefore, the analysis of the importance of risk 
factors in hospitalized medical patients is crucial to deﬁ  ne 
the risk-beneﬁ  t of VTE prophylaxis utilization. A systematic 
review of risk factors for VTE was performed, evaluating 
the current evidence about the factors that could justify the 
use of VTE prophylaxis in this population. The evidence 
about the effectiveness of VTE prophylaxis in these speciﬁ  c 
groups was also reviewed, and evidence-based recommenda-
tions were incorporated into an easy-to-use risk-assessment 
algorithm for VTE.
Methods
Literature search
A computer-based literature search was performed indepen-
dently by two investigators to identify studies evaluating the 
following conditions as risk factors for thrombosis in acutely ill 
medical patients: active rheumatologic diseases (ARD) and in-
ﬂ  ammatory bowel disease (IBD), acute myocardial infarction 
(AMI), admission to ICU, age, cancer, chemotherapy and 
hormonotherapy, central venous catheters (CVC), cerebral 
vascular accident (CVA), congestive heart failure (CHF), dia-
betes, hormonal contraception (HC) and hormonal replacement 
therapy (HRT), hypertension, infections, nephrotic syndrome, 
obesity, paresis and/or paralysis of the lower extremities, 
peripheral vascular disease, pregnancy and puerperium, 
previous VTE, reduced mobility, respiratory diseases (eg, 
chronic obstructive pulmonary disease [COPD], respiratory 
insufﬁ  ciency, and respiratory infections), tobacco use, and 
thrombophilias. We also evaluated the efﬁ  cacy of methods 
of VTE prophylaxis in acutely ill medical patients, including 
low dose unfractionated heparin (LDUH), low molecular 
weight heparins (LMWH), and mechanical methods of pro-
phylaxis. We searched the English language and non-English 
language literature by using MEDLINE, LILACS databases, 
and the Cochrane Central Register of Controlled Trials from 
the earliest searchable dates through August 2004. Annals 
of important meetings were also searched for abstracts from 
1998 onwards. The reference lists of published reviews were 
also evaluated.
Data collection
Inclusion criteria for the systematic review were established 
before the literature search. We included randomized-
controlled trials, cohorts, and case-control studies with at 
least 10 subjects evaluating risk factors or efﬁ  cacy of pro-
phylactic methods for VTE. Two authors read all retrieved 
studies and made the ﬁ  nal decision on which studies met the 
inclusion criteria. All data were abstracted independently and 
in duplicate by two of the authors using a standardized data 
collection form. Discrepancies in the data abstracted were 
resolved by consensus among the authors and the working 
committee.
Levels of evidence
The level of evidence of each study was classified based 
on the American Heart Association, American College of 
Cardiology, and European Society of Cardiology (AHA/
ACC/ESC) guidelines for the management of patients 
with supraventricular arrhythmias (Blomstrom-Lundqvist 
et al 2003). These criteria were adapted to allow evalua-
tion of studies about efficacy of methods of VTE prophy-
laxis and risk factors for VTE. Tables 1A and 1B show 
the levels of evidence and Table 2 shows the strength of 
recommendations.
Table 1 Classiﬁ  cation of levels of evidence for the studies
1A
Level of evidence
Studies about risk factors
A Evidence derived from several RCTs, cohorts using 
screening methods for VTE and/or case-control 
studies suggesting that the risk factor is directly 
associated with the disease.
B Evidence derives from a limited number of RCTs, 
cohorts and/or case-control studies, or with 
conﬂ  icting information and/or divergence of opinion 
that the risk factor is directly associated with the 
disease.
C Evidence from RCTs, cohorts and/or case-control 
studies, that the risk factor is NOT directly associ-
ated with the disease.
1B
Level of evidence
Studies about treatment, prevention or 
etiology
A Evidence derived from RCTs.
B Evidence derived from RCTs with methodologic 
ﬂ  aws, or published only as abstracts, or nonrandom-
ized studies, or observational registries.
C Primary basis for the recommendations was 
expert’s consensus.
Abbreviations: RCTs, randomized controlled trials;  VTE, venous thromboembolism.Vascular Health and Risk Management 2007:3(4) 535
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Results
Risk factors
Each risk factor was evaluated separately as much as pos-
sible. The risk factors for VTE in clinical patients, according 
to the level of evidence, are listed in Table 3. Table 4 shows 
the frequency of VTE in hospitalized patients with various 
medical conditions.
Active rheumatologic diseases and inﬂ  ammatory 
bowel disease\
Although rheumatologic diseases represent a heterogeneous 
group of patients, they have usually been considered at-
risk for thrombosis because incidences of VTE of 10% 
to 30% have been demonstrated in hospitalized patients 
with active rheumatologic diseases (Cohen and Quinlan 
2000; Alikhan et al 2003; Rahim et al 2003). Cogo and 
colleagues (1994) in an analysis of 540 patients with 
suspected DVT, detected systemic lupus erythematosus 
(SLE) as a risk factor for VTE (OR 4.3; 95% CI 3.1–5.5). 
However, Orger and colleagues (1997) in a very similar 
study with 277 patients, found different results (OR 0.7; 
p = NS), that were confirmed in a case-control study with 
1,272 SLE patients (OR 1.6; p = NS) (Samama 2000). 
In the secondary analyses of the MEDENOX study 
about the importance of risk factors, the association of 
VTE with rheumatologic diseases was not statistically 
significant (RR 1.6; 95% CI 0.96–2.69, p = 0.11). Based 
on these data, active rheumatologic diseases as a group, 
and SLE in particular, are not clearly related to increased 
VTE risk. However, lupus anticoagulant (LA) and 
anticardiolipin (ACL) antibodies are frequently found 
in rheumatologic patients and are definitely related to 
thrombotic phenomena. Fijnheer and colleagues (1996), 
studying 173 SLE patients, found that LA was associated 
with VTE with an OR of 6.4 (95% CI 2.7–15.4).
Arterial and venous thromboses are common clinical 
ﬁ  ndings in patients with Behcet’ disease (BD) (Koc et al 
1992). ACL has been found in as many as 30% of these 
patients (Zouboulis et al 1993), but other studies demon-
strate vascular thrombosis even when an ACL antibody is 
not found (Kiraz et al 1999; Mader et al 1999). A HLA-B51 
positive is associated with a higher risk of VTE (OR 4.2; 95% 
CI 1.1–16.3) and a HLA-B35 has a protective effect (OR 0.2; 
95% CI 0.04–0.92) (Kaya et al 2002).
IBD was evaluated by Bernstein and colleagues (2001) 
in a retrospective cohort including 2,857 patients with 
Crohn’s disease (CD) and 2,672 with ulcerative colitis 
(UC). Compared with controls both CD and UC patients 
had increased risk for DVT (RR 4.7; 95% CI 3.5–6.3 in CD 
and RR 2.8; 95% CI 2.1–3.7 in UC) and for PE (RR 2.9; 
95% CI 1.8–4.7 in CD and RR 3.6; 95% CI 2.5–5.2 in UC) 
(Kaya et al 2002). Miehsler and colleagues (2004) studied 
618 patients with IBD, 243 patients with rheumatoid arthritis 
and equal number of gender and aged-matched control. The 
authors found that IBD was signiﬁ  cantly associated with a 
higher chance of developing VTE (OR 3.6; 95% CI 1.7–7.8; 
p < 0.001), but that rheumatoid arthritis was not (OR 0.7; 
95% CI 0.2–2.9; p = NS).
Table 2 Classiﬁ  cation of recommendations
Strength of   Recommendations based on evidence
recommendations  and expert opinion
Class I  Conditions for which there is evidence for 
  and/or agreement of opinion that the 
  procedure (or treatment) is useful/effective.
Class II  Conditions for which there is little evidence
  for and/or divergence of opinion that the
  procedure (or treatment) is useful/effective.
  a  The weight of evidence or opinion
   favors the procedure (or treatment).
 b  Usefulness/efﬁ  cacy is less established
  by evidence or opinion.
Class III  Conditions for which there is evidence for
  and/or agreement of opinion that the
  procedure (or treatment) is NOT useful/
  effective and in some cases may be harmful.
Table 3 Risk factors for VTE in medical patients according to 
the level of evidence
A B 
Age  55 years  Active rheumatologic diseases
AMI Inﬂ  ammatory bowel diseases
Cancer Infections
Chemotherapy Obesity
CHF class III or IV  Peripheral arterial insufﬁ  ciency
CVC and PAC  Reduced mobility
HCVA  Varices/chronic venous insufﬁ  ciency
Hormonotherapy
HRT and HC
ICU admission
ICVA
Nephrotic syndrome
Paresis/paralysis of legs
Pregnancy and puerperium
Previous VTE
Severe respiratory diseases
Thrombophilias
Abbreviations: AMI, acute myocardial infarction; CHF, congestive heart failure; 
CVC, central venous catheters for general use and hemodialysis catheters; HC, 
hormonal contraceptives; HCVA, hemorrhagic cerebral vascular accident; HRT, hor-
monal replacement therapy; ICU, intensive care unit; ICVA, ischemic cerebral vascu-
lar accident; PAC, pulmonary artery catheters;  VTE, venous thromboembolism.Vascular Health and Risk Management 2007:3(4) 536
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In summary, IBD, BD, and positive LA and ACL antibod-
ies in SLE patients should be considered as risk factors for 
VTE (EVIDENCE A). Active rheumatologic diseases as a 
group receive a level of evidence B, while SLE without LA 
or ACL and rheumatoid arthritis should not be considered 
as risk factors for VTE.
Acute myocardial infarction
The risk for VTE in acute coronary syndromes’ patients is 
high, but the speciﬁ  c evaluation of VTE risk in this setting has 
become difﬁ  cult because the use of heparin and other medi-
cations that interfere directly with the coagulation system is 
now routine. Most data about VTE risk in acute coronary 
syndromes come from old studies, with small number of 
patients, comparing placebo with some kind of prophylaxis. 
One study showed an incidence of DVT as high as 62.5%, 
when the treatment for AMI was basically absolute bedrest 
for 5 days (Zawilska et al 1989). In a study comparing LDUH 
with placebo, PE was detected in 12.2% (5/41) in the placebo 
group, compared with 0/37 in the heparin group (Emerson 
and Marks 1977). AMI should therefore, be considered a risk 
factor for VTE (EVIDENCE A).
Admission to ICU
Several studies that employed screening for DVT in criti-
cally ill patients showed that admission to an ICU is a risk 
factor for VTE (RR 1.8 to 2.9) (Cade 1982; Ibarra-Perez 
et al 1988; Hirsch et al 1995; Goldberg et al 1996; Marik 
et al 1997; Kapoor et al 1999; Fraisse et al 2000; Goldhaber 
et al 2000). The incidence of DVT in clinical ICUs is very 
high, particularly in patients receiving no prophylaxis (25% 
to 31%), compared with those that receive some form of pro-
phylaxis (11 to 16%) (EVIDENCE A) (Cade 1982; Kapoor et 
al 1999; Fraisse et al 2000; Goldhaber et al 2000). Besides, 
PE is found in up to 27% of ICU patients that undergo 
autopsy. Although PE contributes to death in about 12% of 
ICU patients, it is suspected before death in only 30% of 
the cases. ICU patients have in general 2 to 4 additional risk 
factors for VTE, not including reduced mobility (Ryskamp 
and Trottier 1998; Geerts and Selby 2003). Nevertheless, 
according to several reports, the utilization of prophylaxis 
in ICU patients had been quite irregular (Ibrahimbacha and 
Alnajjar 1998; Levi et al 1998; Ryskamp and Trottier 1998; 
Rocha and Tapson 2002; Geerts and Selby 2003; Lacherade 
et al 2003; Rocha et al 2003).
Age
Several epidemiologic studies have shown that the 
incidence of VTE increases exponentially with aging. It 
is not clear if the reasons for this are changes in clotting 
mechanisms or the presence of thrombogenic comorbidities 
(Anderson et al 1991; Silverstein et al 1998). In a study 
conducted in Oslo, the incidence of VTE increased from 
1:10,000 at age 20 to 1:1,000 at age 50 (Strekerud et al 
1998). Other studies showed different age cutoffs for 
signiﬁ  cant increase in risk of VTE: RR 1.75 for age >65 
years, 1.51 for age >75 years and 2.0 for age >85 years 
(Knifﬁ  n et al 1994; Alikhan et al 2004; Oger 2000). In 
the study EPI-GETBO, the authors screened 234 medical 
patients on the day of admission with Doppler ultrasound, 
and found that the prevalence of asymptomatic DVT, 
among patients older than 80 years, reached 17.8% (95% 
CI 8.5–32.6) and the incidence 6.0 per 1,000 patients-
day (95% CI, 0–12.7) (Oger et al 2002a). In the study
performed in the community of Worcester, MA, the risk of 
VTE almost doubled at each decade from the 5th decade 
on (RR 1.9) and the incidence of VTE was 62:100,000, 
starting at age 50 (Anderson et al 1991). For the same 
age, others studies showed an incidence of VTE reaching 
100:100,000 (Silverstein et al 1998; Hansson et al 1999). 
Therefore, we conclude that there is a progressive increase 
in VTE risk with advancing age, and that age over the 5th 
decade should be considered as an additional risk factor 
for VTE in medical patients (EVIDENCE A).
Cancer, chemotherapy, and hormonotherapy
Association between cancer and thromboembolism is 
known since 1865, when Trousseau described migratory 
thrombophlebitis as a sign for underlying pancreatic can-
cer (EVIDENCE A). Since then, many others neoplasias 
have been associated with VTE (Table 5) (Pinzon et al 
1986; Thodiyil and Kakkar 2002). This high incidence of 
Table 4 Frequency of DVT in hospitalized patients according to 
their medical condition
Condition DVT  (%)
CVA 28–75
CHF class III or IV  15–71
AMI 10–63
Nephrotic syndrome  14–43
ICU admission  25–31
Active rheumatologic diseases  10–30
Severe respiratory diseases  9–29
Infection 7–16
Abbreviations: AMI, acute myocardial infarction; CVA, cerebral vascular accident; 
CHF, congestive heart failure; DVT, deep venous thrombosis; ICU, intensive care 
unit. 
Note: Frequency based on studies using screening for DVT in patients without 
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VTE may be explained not only by the hypercoagulability 
but also by the action of some antineoplastic agents and 
the frequent venous catheterization. In some studies the 
higher incidences of DVT were observed in patients with 
pancreas, ovarium, liver, and brain cancer, while others 
indicate breast, lung, genital, urinary, stomach and colon 
cancers as the most frequently related to VTE (Coon 1976; 
Bussani and Cosatti 1990; Sorensen et al 1998). In a series 
of 21.530 autopsies, 29% of the patients had cancer and 
the most common were ovarium, extrahepatic biliary tree, 
and stomach (34.6%, 31.7%, and 15.2%, respectively), 
while esophagus, larynges, leukemia, and lymphoma had 
the lower prevalences (Coon 1976; Bussani and Cosatti 
1990; Sorensen et al 1998).
Chemotherapy and hormonotherapy may also be 
thrombogenic (EVIDENCE A). However, it’s difficult 
to separate the effect of the treatment from the effect of 
the cancer itself. Several studies have shown that VTE 
is more common during chemotherapy in breast cancer 
patients, compared with the period without treatment 
(6.8% vs 17.6%) (Goodnough et al 1984; Levine et al 
1988; Saphner et al 1991; Pritchard et al 1996). Saphner 
and colleagues (1991) observed a higher incidence of 
VTE when tamoxifen was used. In a study with mieloma 
patients, Zangari and colleagues (2001) observed that 
addition of thalidomide to chemotherapy was associated 
with an important increase in DVT incidence (28% vs 
4%, p = 0.002).
Central venous catheters
Several variables are implicated in the increased thrombo-
genicity associated with central venous catheters (CVC-
thrombosis) and DVT in patients using catheters (Table 6). 
Given the high variability of catheter-related factors and 
underlying diseases, studies evaluating CVC-thrombosis 
are quite heterogeneous. Besides, the diagnostic methods 
for thrombosis and the primary objectives of these studies 
are extremely variable, which make it difﬁ  cult to group 
then in order to make speciﬁ  c recommendations. For these 
reasons, we discuss thrombosis prophylaxis according to 
the purpose of the catheter: for chemotherapy in cancer 
patients, for parenteral nutrition (PN) and for general use 
in ICU patients. We brieﬂ  y discuss also the evidence for 
pulmonary artery catheters and hemodialysis catheters as 
risk factors for thrombosis.
Several studies show that the incidence of thrombosis 
is higher in the catheterized veins than in contralateral 
veins (Raad et al 1994; Durbec et al 1997b; Mian et al 
1997; Martin et al 1999; Joynt et al 2000). Besides, in 
RCTs of prophylaxis, the incidence of CVC-thrombosis 
is 5%–18% in the groups that receive prophylaxis and 
4%–62% in the groups that do not receive prophylaxis. 
Therefore, central venous catheters constitute additional 
Table 5 Relative risk for VTE in different neoplasias
Origin  Patients   Total of   RR (95% CI)
 with  VTE  patients
Head and neck  35  20,924  0.29 (0.2–0.4)
Bladder 180  74,517  0.42  (0.36–049)
Breast 469  186,273  0.44  (0.4–0.48)
Esophagus 64  147,42  0.76  (058–0.97)
Cervix 53  102,36 0.90  (0.68–1.18)
Liver 121  229,38  0.92  (0.76–1.110)
Prostate 1230  218,743  0.98  (0.93–1.04)
No cancer  46.848  8,177,634  1.0
Rectum 417  65,837  1.11  (1.0–1.22)
Lung 1.504  232,764  1.13  (1.07–119)
Colon 1.320  168,832  1.36  (1.29–1.44)
Renal 278 34,376  1.41  (1.25–1.59)
Stomach 280  32,655  1.49  (1.33–1.68)
Lymphoma 537  52,042  1.80  (1.65–1.96)
Pancreas 488  41,551  2.05  (1.87–2.24)
Ovarium 327  26,406  2.16  (1.93–2.41)
Leukemia 591  47,234  2.18  (2.01–2.37)
Brain 184 13,529  2.37  (2.04–274)
Uterus 226  11,606  3.34  (2.97–3.87)
Table 6 Factors associated with venous thrombosis in patients 
with catheters
Variables Relative  risk
Catheterization of femoral vein1  4.7–6.0 (OR 7.7–23.5)
Catheterization of axilary, subclavian or   3.9–11.6
internal jugular veins2
Catheterization of femoral vein vs. subclavian   4.7–7.4
or internal jugular veins3
Catheterization of internal jugular vein   4.1
vs. subclavian vein4
Catheterization of left subclavian vein vs.   1.2
right subclavain vein5
Infusion of parenteral nutrition vs.   2.6
other solutions6
Catheter material (polyvinyl or polyethylene   3.6–6.0
vs. polyurethane or silicone)7
Catheter duration8 1.04
Number of attempts to insertion (one vs. two)9 11.8
Long-term central catheters vs. long-term   2.2
peripherakl catheters10
Catheters in patients with anti-thrombin   OR 8.4
III deﬁ  ciency11
Catheters in patients with factor V Leiden12 2.3
Notes: 1(Trottier et al 1995; Durbec et al 1997a; Mian et al 1997; Joynt et al 2000); 
2(Kerr et al 1990; Martin et al 1999); 3(Trottier et al 1995; Merrer et al 2001); 
4(De et al 1997; Timsit et al 1998); 5(Gould et al 1993; De et al 1997); 6(Koksoy et al 
1995); 7(Bozzetti et al 1983; Monreal et al 1994); 8(Brismar et al 1981; Ibrahim et al 
2002); 9(Koksoy et al 1995); 10(Kuriakose et al 2002), 11(Lokich and Becker, 1983; 
De et al 1995); 12(Van Rooden et al 2004)Vascular Health and Risk Management 2007:3(4) 538
Rocha et al
risk factors for VTE in clinical patients (Heit et al 2000) 
in general and in oncologic patients (Bern et al 1990; 
Balestreri et al 1995; De et al 1997) in particular (EVI-
DENCE A).
Pulmonary artery catheters (Swan-Ganz)
The rate of clot formation in pulmonary artery catheters is 
time dependent and ranges from 66% to almost 100% in 
noncoated catheters with heparin (Hoar et al 1981; Chastre 
et al 1982; Mangano 1982; Mollenholt et al 1987). Never-
theless, the frequency of thrombotic complications reported 
varies considerably, depending on the method of detection 
of the thrombus (Elliott et al 1979). Similarly to other CVC, 
pulmonary artery catheters lead to a 4.5 higher relative risk 
of thrombosis of the catheterized vein as compared with 
the contralateral veins (Meredith et al 1993), and consti-
tute an additional risk factor for VTE (Rocha et al 2003) 
(EVIDENCE A).
Hemodialysis catheters
Although moderate to severe renal insufﬁ  ciency is associ-
ated with higher risk of bleeding (Lohr and Schwab 1991), 
thromboembolic events are also quite common in patients 
with renal failure. Chronic hemodialysis patients present high 
incidence of thrombophilias, frequently utilize recombinant 
erithropoetin, which may have a prothrombotic effect and 
present also VTE risk factors that are less commonly recog-
nized, such as hyperhomocysteinemia, endothelial dysfunc-
tion and markers of systemic inﬂ  ammation (Casserly and 
Dember 2003). In a study of the US Renal Data System with 
76,718 renal failure patients on chronic dialysis in 1996, the 
incidence of PE was 149.9/100,000, while the incidence of 
PE in the general US population was 24.6/100,000 (Tveit 
et al 2002). Furthermore, thrombosis of the venous access is 
another well established condition in these patients, affecting 
arterial-venous ﬁ  stulas, grafts and double-lumen catheters 
for hemodialysis (Fan and Schwab 1992). These catheters 
are most commonly used as temporary vascular accesses but 
in some instances, allow hemodialysis for longer periods 
(Shusterman et al 1989). Catheter malfunction is quite 
common and the incidence of CVC-thrombosis in these 
patients is up to 46% (Fan and Schwab 1992; Beenen et al 
1994), however, the need for catheter removal is rare. Also, 
the cannulation of subclavian veins lead more frequently to 
thrombosis and/or stenosis than the cannulation of internal 
jugular veins (Vanherweghem et al 1986; Beenen et al 
1994; Agraharkar et al 1995), particularly on the left side 
(Clark et al 1990). Thus, there is evidence that hemodialysis 
catheters, similarly to other CVC constitute an additional risk 
factor for VTE (EVIDENCE A).
Cerebral vascular accident
Hospitalized patients with CVA present one of the 
highest rates of VTE among general medical patients, 
ranging from 28% to 75% and affecting particularly the 
paralyzed limb (McCarthy et al 1977). In a retrospective 
cohort were analyzed 1,953 patients with hemorrhagic 
CVA and 15,599 patients with ischemic CVA (Gregory 
and Kuhlemeier 2003). The authors found a prevalence 
of VTE four-fold higher for patients with hemorrhagic 
CVA and even after controlling for severity of disease 
and duration of hospitalization, hemorrhagic CVA was 
an independent risk factor for VTE with an OR of 2.6 
(95% CI 1.5–4.6). In another study, PE was found to be 
the immediate cause of death in 5% of stroke patients 
(Pambianco et al 1995). For these reasons both ischemic 
and hemorrhagic CVA must be considered important risk 
factors for VTE (EVIDENCE A).
Congestive heart failure
Many studies have shown that CHF is related to VTE, 
especially in patients with reduced mobility. In a case-
control study with 790 patients, CHF increased signifi-
cantly the risk for VTE (OR 2.6; 95% CI 1.4–4.7) (Howell 
et al 2001). Besides, the lower the ejection fraction the 
higher the risk of VTE: OR 38.3 for EF <20%; 2.8 for 
EF from 20% to 40%, and 1.7 for EF >45%. In a cohort 
study with 1,250 patients, Heit and colleagues (2000) 
detected CHF as an independent risk factor for VTE in 
patients presenting with fatal PE at autopsy (OR 2.8; 
95% CI 1.8–4.2). Samama, in another case-control study, 
also identified CHF as a risk factor for VTE in ambulato-
rial patients (OR 2.9; 95% CI 1.5–5.6) (Samama 2000). 
Even in patients treated with anticoagulants due to a 
previous VTE episode, CHF was considered an inde-
pendent risk factor for new VTE episodes (OR 2.3; 95% 
CI 1.1–5.0) (Douketis et al 2000). Although an analysis 
of the MEDENOX study failed to consider CHF as an 
independent risk factor for VTE, the risk associated with 
CHF was observed to be higher among patients with more 
severe functional compromise (RR 0.87; 95% CI 0.6–1.3 
for New York Heart Association [NYHA] class III and 
RR 1.3; 95% CI 0.74–2.34 for NYHA class IV). CHF 
must be considered an important risk factor for VTE, 
particularly among patients with NYHA classes III and 
IV (EVIDENCE A).Vascular Health and Risk Management 2007:3(4) 539
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Hormonal contraception and hormonal replacement 
therapy
HRT and HC increase the risk for VTE by 2 to 6 times 
(EVIDENCE A). Recently, two well designed RCTs con-
ﬁ  rmed the association between VTE and HRT (Hulley et al 
1998; Rossouw et al 2002). In the HERS Study (Heart and 
Estrogen/progestin Replacement Study), 2,763 women with 
coronary disease were followed prospectively and an increase 
in the risk for VTE was noted among those women treated 
with estrogen and progesterone (RR 2.7; 95% CI 1.4–5.0 
for VTE and RR 2.8; 95% CI 0.9–8.7 for PE). A few years 
later, in the Women’s Health Initiative (WHI), the group 
receiving HRT had a RR of 2.1 (CI 95% 1.6–2.8) for the 
development of VTE when compared to the placebo group. 
The risk is higher in the ﬁ  rst year of HRT use (Perez et al 
1997; Hoibraaten et al 1999; Miller et al 2002), especially 
in the presence of previous history of VTE (Hoibraaten et al 
2000). Scarabin and colleagues (2003) showed that the risk 
of VTE was higher with oral, compared with transdermic, 
administration of HRT (RR 4.0; 95% CI 1.9–8.3).
Several observational studies and some RCTs have 
documented a RR 3 to 6 times higher in HC users, compared 
with nonusers (EVIDENCE A) (Jick et al 1995; Lewis et al 
1996; Douketis et al 1997; Vandenbroucke et al 2001). In a 
multicentric, international case-control study including 1,143 
cases of VTE and 2.998 controls, HC was associated with 
an OR of 4.1 (95% CI 3.1–5.6) in European women and to 
an OR of 3.2 (95% CI 2.6–4.1) in women from developing 
countries (WHO 1995). As for HRT, the risk is higher during 
the ﬁ  rst year of use (Suissa et al 1997; Lidegaard et al 1998), 
and it seems also higher for the 3rd generation hormones 
(desogestrel and gestoden) (Kemmeren et al 2001).
Infections
Several cohorts and prospective randomized trials have indi-
cated the association between infections and VTE. However, 
most patients included in these studies have lung infections 
and are described in the speciﬁ  c section about respiratory 
diseases. The SIRIUS study (Samama 2000) included 1,272 
ambulatory patients and demonstrated that infection is a risk 
factor for VTE (OR 1.95; 95% CI 1.31–2.92). However, in this 
study the site of the infections are not reported. Kierkegaard 
and colleagues (1987) studied 101 acutely ill patients with 
labeled ﬁ  brinogen and found that those with pneumonia or 
cardiac diseases had an incidence of DVT of 20% while the 
patients with other diagnoses had an incidence of DVT of 
only 4%. In this study, 4 of the 22 patients with pneumonia 
had DVT, while none of the patients with urinary tract 
infection, bronchitis, acute enterocolitis or sepsis developed 
DVT. In the prospective registry ‘DVT FREE’, Goldhaber 
and Tapson (2004) evaluated 5,451 patients with acute DVT 
conﬁ  rmed by Doppler ultrasound, demonstrating that 22% 
of the patients had an infection as one of the comorbidi-
ties (pneumonia in 7%, sepsis in 5%, and other infections 
in 10%). They also showed that thoracic infections were 
more common among those with PE and DVT, than among 
those with DVT alone (10% vs 8% p = 0.04). Alikhan and 
colleagues (2004) analyzed the data of 866 patients of the 
MEDENOX study, demonstrating that the acute infections 
were one of the main risk factors for VTE in the univariate 
(RR 1.47; 95% CI 1.47–2.14) and multivariate analyses (OR 
1.74; 95% 1.12–2.75). These data suggest that infections are 
an additional and frequent risk factor for VTE, especially in 
hospitalized patients (EVIDENCE A for pulmonary infection 
and B for the other infections).
Nephrotic syndrome
The association between nephrotic syndrome (NS) and 
thromboembolic events is recognized since 1837 (Trew et al 
1978). Until the 70s, some authors suggested that renal vein 
thrombosis was possibly the cause of the NS (Kendall et al 
1971; Bennett 1975). Nevertheless, several studies conﬁ  rmed 
that the thrombotic episodes are a consequence of the factors 
leading to the hypercoagulability found on the NS (Llach 
et al 1975, 1980; Noel et al 1979; Llach 1985; Bellomo et 
al 1993) The global incidence of thrombosis in NS is 43% 
(Bellomo and Atkins 1993), but PE and DVT affect about 
11% of the patients (Nickolas et al 2003). The frequency 
of renal vein thrombosis in the membranous NS, in adults, 
varies among studies from 5% to 60% (Orth and Ritz 1998; 
Nickolas et al 2003). These episodes are symptomatic in only 
10% of the cases (Orth and Ritz 1998), and all episodes can 
be accurately detected by computed tomography (Gatewood 
et al 1986). Rostoker and colleagues (1995) reviewed 13 
prospective studies, including 682 patients with NS, show-
ing that the incidence of renal vein thrombosis was 21.4% 
(95% CI 18%–25%). These authors reviewed also three 
other studies with 148 patients and found that incidence 
of PE was 14% (95% CI 9%–21%). Thromboembolic 
phenomena, particularly renal vein thrombosis, are more 
common with membranous lesions (Wagoner et al 1983; 
Llach 1985; Nickolas et al 2003), and possibly when serum 
albumin is <2g/dL (Kauffmann et al 1978; Kuhlmann et al 
1981; Robert et al 1987; Nickolas et al 2003). For hospital-
ized patients with reduced mobility, NS is a risk factor for 
VTE (EVIDENCE A).Vascular Health and Risk Management 2007:3(4) 540
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Obesity
There are many studies that evaluate obesity direct or indi-
rectly as a risk factor for VTE leading to some debate about 
the importance of it as a risk factor. Alikhan and colleagues 
(2004), analyzing the data of the MEDENOX study, did not 
ﬁ  nd a signiﬁ  cant correlation between obesity and VTE (RR 
1.04; 95% CI 0.69–1.60). Grady and colleagues (2000), 
evaluating women with body mass index (BMI) above 27, 
also failed to ﬁ  nd such a correlation. It is important to men-
tion that in both studies the identiﬁ  cation of obesity as a 
risk factor was a secondary objective and the analysis was 
done post hoc. Besides, the deﬁ  nition of obesity currently 
accepted as the BMI 30 Kg/m², is not used in all studies. 
For example, in a study of consecutive out-patients with 
clinical suspicion of VTE, Cogo and colleagues (1994) 
deﬁ  ned obesity as 30% excess above ideal body weight and 
did not ﬁ  nd that obesity was a risk factor for VTE. Heit and 
colleagues (2000), in a population based case-control study 
reached the same conclusion.
On the other hand, several studies do implicate obesity as 
a risk factor for VTE. Blaszyk and colleagues (1999) found 
in an autopsy study (n = 7,227) a higher incidence of VTE 
in obese (67%) than in nonobese (14%), RR 2.97 (95% CI 
1.78–4.93). Four prospective cohort studies support theses 
ﬁ  ndings, with RR ranging from 2.0 to 3.92 (Cogo et al 
1994; Goldhaber et al 1997, 1983; Hansson et al 1999). 
Although there is some debate, the evidence from prospec-
tive trials evaluating risk factors support the correlation 
between obesity and VTE. Nevertheless, the RR for obesity 
is relatively low (between 2 and 3) but increases signiﬁ  cantly 
when there are additional risk factors for VTE. Indeed, the 
RR rises from 2 to 10 with the use of HC in obese patients 
(Abdollahi et al 2003). In summary, we conclude that obe-
sity is an important coadjuvant for the development of VTE 
(EVIDENCE B).
Paresis/paralysis of the lower extremities
There is supporting evidence that paresis or paralysis of 
the lower extremities is associated with VTE, even when 
not secondary to CVA (EVIDENCE A). In a study with 
143 patients that developed acute hemiplegia, the incidence 
of VTE was 26% and the risk was higher during the ﬁ  rst 
4 weeks (Rentsch 1987). Pottier and colleagues (2002) 
studied the presence of risk factors among 450 hospitalized 
medical patients and found that paralysis was associated 
with an increased chance of VTE (calculated OR 12.5; 95% 
CI 1.5–104.5). The same result was seem in a case-control 
study with 620 patients older than 65 years (OR 2.1; 95% 
CI 1.0–4.1) (Weill-Engerer et al 2004). Patients with paresis 
or paralysis of the legs must be considered as at-risk for VTE, 
particularly during the acute setting (EVIDENCE A).
Peripheral vascular diseases
The impact of varices of the lower extremities as an additional 
risk factor for VTE in medical patients is controversial. There 
are few studies evaluating the theme and there is no evidence 
that surgical treatment of the varicose veins decreases the 
potential risk of VTE. Kakkar and colleagues (1970) showed 
that the incidence of VTE by labeled ﬁ  brinogen in surgical 
patients with mild to severe varices was 56.5%, leading to a 
RR of 2.3. The reason for such a high incidence of VTE in 
patients with varices is not known but one of the possibili-
ties is that the varices may be a consequence of previous and 
undiagnosed DVT. Recently, Heit and colleagues (2000) 
demonstrated in a population-based, case-control study that 
varices are associated with risk of VTE in medical patients, 
but the risk decreases with age: OR 4.2 at age 45, 1.9 at age 
60 and 0.9 at age 75. In another analysis of the same data 
(Heit et al 2002), the attributable risk of VTE to varices 
was 6%; but after adjustments for other confounders, such 
as hospitalization, trauma, cancer and chemotherapy, CHF 
and CVA, CVC or pacemaker, the risk associated with 
varices became zero. Some cohort studies also failed to 
demonstrate an independent association between varices 
and VTE (Goldhaber et al 1983; Kierkegaard et al 1987). On 
the other hand, prospective studies with good methodology 
(Alikhan et al 2003; Oger et al 1997) and case control stud-
ies (Samama 2000; Pottier et al 2002) showed that varices 
(OR  2.5 and RR 4.2) and venous insufﬁ  ciency (OR  1.7) 
were signiﬁ  cantly associated with VTE in medical patients. 
Furthermore, one case-control study in ambulatory patients 
with clinical suspicion of DVT or PE showed that peripheral 
arteriopathy was related to an higher chance of VTE (OR 1.9) 
(Cogo et al 1994). Therefore, peripheral venous and arterial 
diseases may be considered as cofactors for the development 
of thrombosis (EVIDENCE B).
Pregnancy and puerperium
Pregnancy is a well known condition related to increased risk 
of thrombosis (Samama 2000), that persists even a few months 
after delivery (EVIDENCE A). It is estimated that the risk 
for VTE during pregnancy increases 3 to 4 times, probably 
because of the increase in procoagulant factors, such as factor 
VIII and in the resistance to activated protein C. Samuelsson 
and Hagg (2004), in a population-based study with more 
than 24,000 women, reported an incidence of VTE during Vascular Health and Risk Management 2007:3(4) 541
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pregnancy and postpartum of 103:100,000 (95% CI 55–177). 
Besides, fatal PE remains one of the most important complica-
tions during pregnancy and puerperium, especially in those 
women older than 40 years (Franks et al 1990).
Previous VTE
Previous VTE has been consistently described as a risk factor 
for the development of VTE in several scenarios: hospital-
ized and ambulatorial patients and in the general population 
(EVIDENCE A). The case-control study SIRIUS (Samama 
2000) revealed a strong tendency to new thrombotic events 
in ambulatorial patients with previous history of VTE (OR 
15.6). In a prospective study, Oger and colleagues (1997) 
showed that medical patients with suspected DVT and history 
of VTE had increased chance of conﬁ  rming the diagnosis by 
venography (OR 1.7). In 2003, Tosseto and colleagues (2003) 
also demonstrated increased risk of VTE in individuals with 
previous history of this condition (OR 6.8). A case-control 
study showed that previous history was an important risk 
factor for VTE also in hospitalized medical patients (OR 4.7) 
(Bonifacj et al 1997). Another case-control study showed that 
in hospitalized medical patients older than 64 years-old, pre-
vious VTE was independently associated with the develop-
ment of VTE during hospitalization (OR 3.4) (Weill-Engerer 
et al 2004). In the analysis of VTE risk factors based on the 
MEDENOX study (Alikhan et al 2004), previous history 
was associated with the development of VTE, in univariate 
(RR 1.8; p = 0.02) and multivariate logistic regression (RR 
2.1; p = 0.02). Thus, previous history of thrombosis should 
be considered as an additional risk factor for VTE in medical 
patients (EVIDENCE A).
Reduced mobility
It is not known exactly what level and duration of immobility 
is associated with increased risk of VTE. What is recognized 
is that when important risk factors are present, even subtle 
reductions in mobility increase the overall risk of VTE. It 
is believed that when patients are able to ambulate to the 
bathroom or on the hallways, but have to come back, for any 
reason (eg, need for intravenous infusions or oxygen therapy, 
generalized weakness, pain, or dyspnea on exertion), and 
stay in bed or chair while hospitalized with an acute illness, 
they are at-risk for VTE.
Some studies tried to identify the loss of mobility as 
the main factor leading to VTE. Motykie and colleagues 
(2000) evaluated 1,000 patients with Doppler ultrasound 
for suspected DVT and noted that there was a signiﬁ  cant 
correlation between loss of mobility for more than 3 days 
and development of DVT. In a large case-control study with 
1,272 ambulatory patients, Samama (2000) showed that 
standing for more than 6 hours and resting in bed or chair 
were associated with an increased odds of VTE (OR 1.9; 95% 
CI 1.1–3.1 and OR 5.6; 95% CI 2.3–13.7, respectively). Simi-
larly, Heit and colleagues (2000) showed that hospitalization 
or admission to a long-term care facility increased the risk 
of VTE (OR 8.0; 95% CI 4.5–14.2). Other studies identify 
the reduction of mobility as a risk factor for VTE, but the 
deﬁ  nition of decreased mobility is either not clearly stated 
or it is quite variable, including complete bed rest for  5 
days (Anderson et al 1992), partial or complete bedrest for 
at least 10 days (Harenberg et al 1996), reduced mobility 
for more than half of the day, at least during 7 days (Lechler 
et al 1996). Other authors noted that more serious loss of 
mobility, such as the incapacity to walk independently for 
more than 10 meters were frequently associated with the 
development of VTE (Alikhan et al 2003). In a recent case-
control study of hospitalized patients older than 65 years, 
reduced mobility was an independent risk factor for VTE 
(OR 1.73 to 5.64), depending on the degree of immobility 
(Table 7) (Weill-Engerer et al 2004). The risk was higher 
in patients with more severe limitation of mobility (bedrest 
vs wheel-chair) and when the loss of mobility was recent 
(<15 days vs ≥30 days).
Based on presented data, we believe that the patient who 
stays in bed or chair for more than half of the day (excluding 
sleep time) must be considered as having reduced mobility 
and is at-risk for VTE (EVIDENCE B). The immobility that 
is more recent and severe is more strongly associated with 
the development of VTE.
Respiratory diseases
Respiratory diseases such as COPD and pneumonia are 
frequently cited as VTE risk factors, but studies evaluating 
speciﬁ  cally the impact of these conditions in the incidence 
of VTE are rare. Besides, the diagnosis of VTE in COPD 
patients is usually a challenge because PE may present 
simply as worsening of dyspnea in a patient with chronic 
respiratory failure. On the study performed in the community 
of Worcester, MA, the diagnosis of COPD was present in 
18% of those with DVT and in 34% of patients with PE 
(Anderson et al 1991). In autopsy studies, DVT has been 
diagnosed in 18% to 51% of COPD patients, giving an 
OR of 1.6 for emphysema as compared with controls with 
median age 81 years-old (Mitchell et al 1968; Janssens et al 
2001). In prospective cohorts of patients with exacerbation of 
COPD, DVT was detected in 9% of patients by venography Vascular Health and Risk Management 2007:3(4) 542
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and/or labeled ﬁ  brinogen (Prescott et al 1981), in 11% by 
Doppler ultrasound (Schonhofer and Kohler 1998; Erelel et al 
2002), and in 29%, when combining ventilation-perfusion 
scanning and Doppler ultrasound (Mispelaere et al 2002). 
Patients treated for VTE with oral anticoagulation in a RCT 
were analyzed, and the authors demonstrated that chronic 
respiratory diseases increased the risk for recurrence of VTE 
(OR 1.91; 95% CI 0.85–4.26) (Douketis et al 2000). On the 
other hand, the analyses of patients with risk factors for VTE 
in the MEDENOX study surprisingly revealed that chronic 
respiratory disease was not signiﬁ  cantly associated with an 
increased risk (OR 0.6; 95% CI 0.38–0.92)(Alikhan et al 
2004). However, it is worthy noticing that these analyses 
were performed post hoc and based on secondary objectives 
of the MEDENOX study.
Prospective controlled studies evaluating the efﬁ  cacy of 
VTE prophylaxis are helpful in identifying pulmonary condi-
tions as risk factors for VTE because the rates of thrombosis 
can be compared between patients on control and treatment 
groups. Belch and colleagues (1981), in a small study with 
patients with thoracic infection or CHF, showed a signiﬁ  cant 
difference in the incidence of DVT diagnosed by labeled 
ﬁ  brinogen, favoring LDUH (5,000 IU 8–8h) versus placebo 
(4% vs 26%, respectively, p < 0.01). In another RCT, patients 
with exacerbation of COPD, requiring ventilatory support 
(the majority with thoracic infection), were randomized 
to LMWH (nadroparin 3,800 IU AXa or 5,700 IU AXa) 
or placebo (Fraisse et al 2000). Those receiving LMWH 
had signiﬁ  cantly lower incidence of VTE, when compared 
with placebo (28.2% vs 15.5% respectively, p = 0.045). In 
the study THE-PRINCE (Kleber et al 2003), patients with 
severe respiratory diseases (SRD) or CHF were randomized 
to enoxaparin 40 mg/daily or LDUH 5,000 IU three times 
daily. The authors demonstrated that the incidence of VTE 
by venography was high in all patients, without signiﬁ  cant 
differences among all patients receiving enoxaparin and 
LDUH (8.4% vs 10.4%), or among patients with SRD (7.1% 
vs 5.9%). The deﬁ  nition of SRD in this study was the pres-
ence of abnormalities in the pulmonary function tests, arterial 
blood gas analyses or both, and at least one of the following 
conditions: acute exacerbation of COPD, severe secondary 
pulmonary hypertension, pneumonia, interstitial lung disease, 
lung cancer and/or metastasis and life expectancy of less 
than 2 months. This description is broad enough to include 
the main pulmonary diagnoses that are associated with an 
increase risk of VTE in hospitalized medical patients, and 
was therefore, incorporated to our algorithm instead of each 
pulmonary disease separately. In summary, there is some 
controversy about the role of speciﬁ  c respiratory diseases 
as risk factors for VTE in hospitalized medical patients. 
However, in general, patients presenting diagnostic criteria 
for SRD have increased risk for VTE (EVIDENCE A).
Thrombophilias
Hereditary thrombophilias, particularly antithrombin III 
(ATIII), protein C (PC) and protein S (PS) deﬁ  ciencies, 
and factor V Leiden (FVL) are well known risk factors for 
VTE. Several case-control studies and some prospective 
registries show level A evidence for these thrombophilias as 
risk factors for thrombosis (Table 8). In a recent prospective 
registry of thrombophilic families, the incidence of VTE was 
16% among relatives with thrombophilia, against 1% among 
those without thrombophilia (RR 15.7; 95% CI 9.6–28.0) 
(Vossen et al 2004). In a multicenter study with 233 Italian 
families, Bucciarelli and colleagues (1999) showed that 
ATIII deﬁ  ciency is associated with a higher risk for VTE 
than other genetic conditions (RR 4.4 for ATIII vs FVL, 
2.6 for ATIII vs PS, and 1.9 for ATIII vs PC). Simioni and 
colleagues (1999) reported that conditions such as surgery, 
trauma, immobilization, pregnancy, puerperium, and hor-
monal contraception increase the risk for thrombosis in 
patients with ATIII, PS or PC deﬁ  ciencies. Mutation of the 
prothrombin gene has also been associated with increased 
risk for VTE in different populations (OR 2.0 to 11.5) (Poort 
et al 1996; Brown et al 1997; Cumming et al 1997; Hillarp 
et al 1997; Kapur et al 1997; Leroyer et al 1998; Souto et al 
1998; Aznar et al 2000). It is appropriate to conclude that 
hereditary thrombophilias confer additional risk for VTE in 
hospitalized patients (EVIDENCE A).
Hyperhomocysteinemia (HHC) has been considered 
a risk factor not only for arterial disease, but also for 
venous thrombosis. In 1998, den Heijer and colleagues 
(1998) reviewed 8 case-control studies in a meta-analysis, 
and showed correlations between fasting HHC and VTE 
(OR 2.5; 95% CI 1.8–3.5), and methionine-induced HHC 
Table 7 Reduced mobility as a risk factor for VTE
Degree of immobility  OR  95% CI  P
Normal 1.0  -  -
Limited 1.73  1.08–2.75  0.02
Wheel-chair  30 days  2.43  1.37–4.30  0.002
Bedrest  30 days  2.73  1.20–6.20  0.02
Wheel-chair 15–30 days  3.33  1.26–8.84  0.02
Bedrest 15–30 days  3.37  1.00–11.29  0.05
Wheel-chair 15 days  4.32  1.50–12.45  0.007
Bedrest <15 days  5.64  2.04–15.56  0.0008Vascular Health and Risk Management 2007:3(4) 543
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and VTE (OR 2.6; 95% CI 1.6–4.4). Furthermore, the risk 
seems to be even higher in patients older than 60 years (OR 
4.4; 95% CI 1.9–9.8) (Ray 1998). Thus, HHC should be 
considered a risk factor for VTE (EVIDENCE A).
Other risk factors
Although some conditions, such as, systemic arterial 
hypertension, diabetes mellitus and tobacco smoking are 
cited occasionally as potential risk factors for VTE, we did 
not ﬁ  nd enough evidence to justify their inclusion on the list 
of factors that predispose hospitalized medical patients to the 
development of venous thrombosis.
VTE prophylaxis
Compared with surgical patients, there are few studies 
evaluating VTE prophylaxis in medical patients. Besides, 
the great range of clinical conditions and variations in 
individual characteristics make it difﬁ  cult to create a single 
recommendation suitable for all patients or even deﬁ  ne if 
there is superiority of one type or one particular regimen of 
heparin over the others. Table 9 shows the evidence-based 
recommendations for prophylaxis, as they are found in the 
literature, for speciﬁ  c conditions and not for medical patients 
as a group. Table 9 also shows that, in most studies, the 
regimens of heparin involve high prophylactic doses: LDUH 
5.000 IU every 8 hours, enoxaparin 40 mg daily, dalteparin 
5.000 IU daily or nadroparin also in high doses (3.800 IU 
for patients with less than 70 kg and 5.700 IU for those 
weighing 70 kg or more). All these studies have proved the 
efﬁ  cacy of these regimens in decreasing the incidence of 
VTE. This leads to the initial conclusion that medical patients 
beneﬁ  t from high prophylactic doses of heparin. Therefore, 
these high prophylactic doses are the ones recommended 
(GRADE I) for most hospitalized medical patients on the 
algorithm (Figure 1). Only a few studies, usually with very 
few patients and some methodological ﬂ  aws (Harenberg et al 
Table 8 Annual incidence and VTE risk in hereditary thrombophilias
Author, year  Patients/  Design  ATIII  PC  PS  FVL  MPG  Combination
 controls
Finazzi and Barbui 1994  28/53†  PC/8 years  12.0%  2.80%  3.30%  -  -  -
Pabinger et al 1994  44/49  PC  -  2.50%  3.50%  -  -  - 
Koster et al 1995  474/474  CC  OR 2.2–5.0  OR 3.1–6.5  OR 0.7–1.6§  -  -  -
Poort et al 1996  442/463  CC  -  -  -  -  OR 2.8  -
Kapur et al 1997  50/50  CC  -  -  -  -  OR 11.5  -
Hillarp et al 1997  99/282  CC  -  -  -  -  OR 3.8  -
Cumming et al 1997  219/164  CC  -  -  -  -  OR 5.4  -
Brown et al 1997  504  RC  -  -  -  OR 5.8  OR 2.0  -
Faioni et al 1997  327/317  CC  -  -  OR 2.4  -  -  -
Leroyer et al 1998  366/400  CC  -  -  -  x  OR 3.7  OR 4.8
Souto et al 1998  116/201  CC  -  -  -  -  OR 3.1  -
Middeldorp et al 1998  437  RC  -  -  -  0.45%. RR 4.2 -  -
Martinelli et al 1998  150/723  RC  RR 8.1  RR 7.3  RR 8.5  RR 2.2  -  -
Mateo et al 1998  583  RC  OR 21.2  OR 12.6  OR 19.9  -  -  OR 9.0
Sanson et al 1999  94/208†  PC/3 years  1.60%  1.00%  0.40%  -  -  -
Bucciarelli et al 1999  233/513  RC  1.07%  0.54%  0.50%  0.30%
Simioni et al 1999  793  RC  x  x  x  0.11%. RR 2.5   0.40%. RR 10.6
Rodeghiero and   15109  TC  -  OR 1.7  -  RR 3.3  -  -
Tosetto 1999
van Boven et al 1999  48/44  CC  1.10%  -  -  x  x  4.60%
Aznar et al 2000  229/246  CC  -  -  -  OR 6.9  OR 2.4  -
Lensen et al 2000  233  RC  -  -  -  0.56%  -  -
Middeldorp et al 2001  247/470†  PC/3.3 years  -  -  -  0.58%  -  -
Folsom et al 2002ª  14358  PC/8.1 years    RR 3.36
Folsom et al 2002b  335/668  CC  - - -  OR  3.7  -  -
Simioni et al 2002  131/313-248*  PC/4 years  -  -  -  0.17%. RR 6.6 -  -
Oger et al 2002b  621/406  CC  - - -  OR  3.2¥ -  -
Vossen et al 2004  846/1212  CC  -  x  x  0.15%  -  0.84%
Abbreviations:  ATIII, antithrombin III deﬁ  ciency; CC, case-control; FVL, factor V Leiden; MPG, mutation of the prothrombin gene; OR, odds ratio; PC, prospective cohort; 
PC, protein C; PS, protein S; RC, retrospective cohort; RR, relative risk; TC, transversal cohort.
Notes: †Patients/asymptomatic holders; *Patients/asymptomatic holders-controls; §Not a risk factor; ¥Not a risk factor for age >70 years (OR 0.8; 95% CI 0.4–1.7); 
xThrombophilias evaluated in combination.Vascular Health and Risk Management 2007:3(4) 544
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1996; Lechler et al 1996; Samama et al 1999; Leizorovicz 
et al 2004) have shown that low prophylactic doses of heparin 
have efﬁ  cacy. Besides, in the MEDENOX study (Samama 
et al 1999) that compared the high (40 mg) and low (20 mg) 
prophylactic doses of enoxaparin with placebo, only the 
higher dose reduced signiﬁ  cantly the incidence of VTE. In 
the groups receiving 20 mg of enoxaparin, the incidence of 
DVT detected by phlebography was similar to that of the 
placebo group (14.5% vs 15.0%). Finally, a large randomized 
placebo-controlled trial, published after this review had been 
concluded (Cohen et al 2006) showed that fondaparinux, a 
synthetic, selective inhibitor of factor Xa, at a dose of 2.5 
mg/day subcutaneously for 14 days was also effective for the 
prevention of VTE in older acutely ill medical patients.
Four important RCTs evaluated VTE prophylaxis in 
medical patients as a group (Harenberg et al 1996; Lechler 
et al 1996; Samama et al 1999; Leizorovicz et al 2004). 
Together they included 7,735 patients, with average ages 
of 68 to 74 years-old. Diseases and conditions listed as 
risk factors are presented on Table 10. The most common 
All medical patients should be routinely 
evaluated
Age r 40 years
*
and
Reduced mobility
§
Yes
No
No
Mechanical methods
(Intermittent Pneumatic Compression 
and/or elastic stockings) and 
reevaluation in 2 days
No
Yes
Pharmacological prophylaxis indicated
LMWH SC daily
Enoxaparin 40 mg, or dalteparin 5.000 IU
or nadroparin
‡ 3.800 IU (<70 Kg) or
5.700 U (≥70 Kg)
or
LDUH 5.000 IU SC q8 h
For 10 p 4 days
or while risk persists
 * Patients younger than 40 years-old, but with additional 
risk factors, may benefit from VTE prophylaxis.
 § Patient spends more than half of the day time in bed or 
chair (excluding sleep time).
† ICVA – hemorrhage must be excluded with CT or MRI.
HCVA – consider starting prophylaxis on day 10, after 
confirming clinical and radiological stability.
¥Abnormalities in the pulmonary function tests, arterial 
blood gas analyses or both, in patients with COPD, 
pulmonary hypertension, pneumonia, interstitial lung 
diseases, lung cancer and/or metastasis.
‡ Harenberg et al showed a significant increase in 
mortality in patients that received nadroparin compared 
to LDUH.
9
Any additional risk factor?
Active rheumatologic diseases Infection
Admission to ICU Inflammatory bowel disease
Age ≥ 55 years Nephrotic syndrome
AMI Obesity
Arterial insufficiency Paresis/paralysis of legs
Cancer Pregnancy and puerperium
Central catheters and Swan-Ganz Previous VTE
Chemotherapy or hormonotherapy Severe respiratory diseases
¥
CHF class III or IV Thrombophilias
CVA
† Varices/Chronic venous insufficiency
Hormone replacement/contraception
Ambulation and
reevaluation in 2d
Contra-indications?
Active bleeding
Active peptic ulcer
Allergy or heparin induced thrombocytopenia
Coagulopathy (thrombocytopenia or INR >1.5)
Cranial or ocular surgery <2 weeks
Lumbar punction <24 h
Renal insufficiency (Cr clearance <30 mL/min)
Uncontrolled hypertension (>200×110 mm Hg)
Yes
Figure 1 Algorithm for VTE prevention in hospitalized medical patients.Vascular Health and Risk Management 2007:3(4) 547
VTE risk and prophylaxis for hospitalized medical patients
reasons for admission were CHF, respiratory insufﬁ  ciency 
and infection. The most common risk factors were obesity, 
varices, cancer, active rheumatologic disorders and previous 
VTE. Enoxaparin (Lechler et al 1996; Samama et al 1999), 
dalteparin (Leizorovicz et al 2004), nadroparin (Harenberg 
et al 1996), and LDUH (Harenberg et al 1996; Lechler et al 
1996) were used in these studies. Harenberg and colleagues 
(1996) compared nadroparin 3.600 IU with LDUH 5.000 IU, 
every 8 hours in 1,968 medical patients. Although there were 
no differences on the efﬁ  cacy of prophylaxis or on the rate of 
bleeding, more patients in the nadroparin group died (2.8% 
vs 1.2% in LDUH group, p = 0.02). However, Fraisse and 
colleagues (2000) evaluated nadroparin as VTE prophylaxis 
in 223 patients with acute exacerbation of COPD requiring 
mechanical ventilation and demonstrated the efﬁ  cacy of 
this LMWH against placebo, without increased bleeding or 
death rates.
Another important issue is how long the prophylaxis 
should be maintained. It is common belief among physicians 
that as soon as the patient is able to ambulate, the risk is over 
and prophylaxis could be discontinued. However, there is 
no support in the literature for this, and in all studies that 
included hospitalized medical patients with risk factors to 
VTE, prophylaxis was maintained for at least 6 to 14 days 
(Harenberg et al 1996; Lechler et al 1996; Samama et al 1999; 
Kleber et al 2003; Leizorovicz et al 2004). In the PREVENT 
(Leizorovicz et al 2004) study, authors are speciﬁ  c about the 
point that all patients received the medication (dalteparin or 
placebo) for 14 days, even if they were discharged earlier. 
Besides, in the MEDENOX (Harenberg et al 1996; Lechler 
et al 1996; Samama et al 1999; Leizorovicz et al 2004) and in 
the PREVENT (Leizorovicz et al 2004) studies, patients were 
reevaluated several weeks after prophylaxis was ﬁ  nished, and 
symptomatic VTE episodes were detected. We have not found 
any studies testing prophylaxis for less than 6 days. Until new 
data is available, it’s recommended that VTE prophylaxis be 
maintained for at least 6 to 14 days. There is only one study that 
we are aware of—the EXCLAIM study (Extended Prophylaxis 
for Venous Thromboembolism in Acutely Ill Medical 
Patients with Prolonged Immobilization)—that has evaluated 
the extension of prophylaxis beyond 14 days in medical 
patients. The preliminary results of this study were recently 
presented at the XXIth Congress of the International Society 
on Thrombosis and Haemostatis and suggest the extension of 
VTE prophylaxis with enoxaparin 40 mg/day for an additional 
28 days, is beneﬁ  cial for acutely ill medical patients that 
remain with severely impaired mobility and for those with 
moderate impairment of mobility plus 75 years-old, cancer, 
or history of VTE. The ﬁ  nal manuscript has not yet been 
published.
Some conditions represent contraindications to heparin 
use and must have their risk weighed against the potential 
beneﬁ  t of the prophylaxis. Active bleeding, allergies, and 
previous type II heparin induced thrombocytopenia are 
absolute contraindications; thrombocytopenia for other rea-
sons, coagulopathies, recent surgeries, specially cranial and 
ocular, lumbar puncture, uncontrolled hypertension, active 
pepticulcer without bleeding, and renal failure with clearance 
lower than 30 mL/min are also considered contraindications 
(Leizorovicz et al 2004; Samama et al 1999). In patients 
with mild to moderate renal failure, LDUH is preferred over 
LMWH for VTE prophylaxis in medical patients, based on 
level C of evidence (Class IIa). If LMWH are chosen for 
patients with renal insufﬁ  ciency, the measurement of anti-
Xa activity is recommended to adjust LMWH doses (Hulot 
et al 2004).
Conclusion
In summary, VTE prophylaxis is recommended for acutely 
ill, hospitalized medical patients, age 40 years or older, with 
reduced mobility and at least one additional risk factor for 
VTE, as suggested in the algorithm below (Figure 1). Patients 
younger than 40 years of age, but presenting with important 
risk factors, may beneﬁ  t from prophylaxis. When the algo-
rithm for risk assessment indicates that VTE prophylaxis is 
recommended, LMWH once a day (enoxaparin 40 mg, dalte-
parin 5.000 IU, nadroparin 3.800 IU if 70 Kg or 5.700 IU 
if 70 Kg) or LDUH 5.000 UI SC every 8 h should be used 
and maintained for 6 to 14 days, even if the patient resumes 
ambulation or has early discharge. For patients older than 
60 years, fondaparinux 2.5 mg once a day is also an option.   
Table 10 The most common diseases and risk factors for 
VTE found in four large RCTs about efﬁ  cacy of prophylaxis in 
hospitalized medical patients1–4 
Disease/Risk factor  %
Congestive heart failure  30–52
Respiratory disease  24–53
Infection 20–54
Obesity 27–53
Varices 22–27
Cancer 4.6–20
Active rheumatologic disease  7.6–11
Past history of  VTE  3.4–8.4
Estrogen therapy  1.4–1.8
Bowel inﬂ  ammatory disease  0.5–0.8
Notes: 1Harenberg et al 1996; 2Lechler et al 1996; 3Samama et al 1999; 4Leizorovicz 
et al 2004.Vascular Health and Risk Management 2007:3(4) 548
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If there is contraindication for pharmacological prophylaxis, 
mechanical methods of prophylaxis may be considered. 
However, all patients must be frequently reevaluated for the 
appearance of new indications or contraindications for pro-
phylaxis during the hospitalization.
Key points
•  Hospitalized medical patients have increased risk of 
thromboembolic complications.
•  Our multidisciplinary group created an easy-to-use algo-
rithm to facilitate the implementation of evidence-based 
recommendations for prophylaxis of hospitalized medical 
patients into practice.
•  In the absence of contraindications, hospitalized medical 
patients that are older than 40 years of age, have reduced 
mobility and at least one additional risk factor for VTE 
should be given high prophylactic doses of LDUH or 
LMWH for 6 to 14 days.
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